Dr Armstrong has served as a member of the Board of Directors since November 2012 and as Non-Executive Chairman since June 2013. Prior to this, Dr Armstrong led Medical Science and Innovation at Merck Serono, the biopharmaceutical division of Merck KGaA, from 2010 to 2011. Dr Armstrong was also Head of Worldwide Product Development at Bayer AG from 1998 to 2001 and held various positions at ICI plc and Zeneca plc, now AstraZeneca plc, from 1985 to 1998. Dr Armstrong has served as the Chief Executive Officer at five biotechnology companies, including Fulcrum Pharma, CuraGen, which was acquired by Celldex Therapeutics Inc, Bioaccelerate, Provensis and Phoqus. Dr Armstrong is the Non-Executive Chairman of the Boards of Directors of Faron Pharmaceuticals Oy and Caldan Therapeutics Ltd. He is a Non-Executive Director on the Boards of Juniper Pharmaceuticals Inc, which is listed on NASDAQ and Mereo Biopharma Group plc. He is also a Member of the Strategic Advisory Board of HealthCare Royalty Partners. Dr Armstrong received an honours degree in Biochemistry and an MBChB in Medicine from the University of Edinburgh in Scotland. Dr Armstrong is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow of the Faculty of Pharmaceutical Physicians.


Mr Edwards has served as Summit’s Chief Executive Officer and a member of the Board of Directors since April 2012. Prior to joining the Company, Mr Edwards served as interim Chief Executive Officer of the BioIndustry Association, a UK trade organisation, from November 2011 to June 2012, and Chief Executive Officer at Antisoma plc, a biotechnology company specialising in the development of novel drugs for the treatment of cancer, from 1998 to 2011. Mr Edwards also previously served as Vice President of Business Development at Therapeutic Antibodies Ltd. Mr Edwards received a BSc in Biochemistry from Bristol University and a MSc in Economics from the London Business School.


Dr Price has served as a member of the Board of Directors since September 2006. Dr Price spent 28 years with the Glaxo Group of companies, where he held several executive positions including Managing Director of Glaxochem Ltd from 1993 to 1995 and Research Director of Glaxo Group Research from 1989 to 1993. Dr Price also served as a Non-Executive Director of Shire plc, a biopharmaceutical company that is listed on the London Stock Exchange and NASDAQ, from 1996 to 2009, during which time he was involved in developing the company into one of the UK’s largest life sciences companies. Dr Price has previously held directorships at Chiroscience plc, Celltech Group plc, Pharmagene plc, Antisoma plc and BioWisdom Ltd. Dr Price received a BSc in Chemistry and a PhD in Chemistry from the University of Sheffield. He is a Fellow of the Royal Society of Chemistry.


Professor Davies has served as a member of the Board of Directors since November 2013 and previously served as a member of our Board of Directors from 2004 to February 2013.  Professor Davies is a distinguished academic who has been professor at the University of Oxford for over 20 years and was elected to the Waynflete Chair of Chemistry in 2006, one of the most prestigious academic posts in UK science. Professor Davies’ areas of expertise include medicinal and asymmetric chemistry and he has published extensively and received numerous awards in his field. Professor Davies co-founded Summit, as well as other University of Oxford spin-out companies. He was the founder and Non-Executive Chairman of MuOx Ltd, OxRay Ltd, and he was Non-Executive Chairman of Scientific Research Capital Ltd. He is a Founder and Non-Executive Director of OxStem Ltd, OxStem Oncology Ltd, OxStem Ocular Ltd, OxStem Cardio Ltd and OxStem Neuro Ltd, and is a Non-Executive Director of Oxford University Innovation Ltd (formerly Isis Innovation Ltd). Professor Davies received a BA in Chemistry from the University of Oxford, a DPhil in Organic Chemistry from the University of Oxford, and a DSc. in Organic Chemistry from the University of Paris.


Mr Zambeletti has served as a member of our Board of Directors since May 2014. Mr Zambeletti is a highly respected figure within the life sciences sector and has served as an independent strategic advisor to life sciences companies since 2013, focussing on mergers and acquisitions, out-licensing deals, and financing strategy. Prior to this, Mr Zambeletti worked in investment banking for 19 years, during which time he led the European Healthcare Investment teams at JP Morgan and at Credit Suisse. He is a Non-Executive Director of Nogra Pharma Ltd, an Irish biotechnology company, and of Advanced Accelerator Applications, a Swiss nuclear diagnostics and therapeutics company. Mr Zambeletti began his career as an accountant at KPMG. He received his degree in Business Administration from Università Bocconi, Milan.


Ms Andrews has served as a member of the Board of Directors since September 2014. Most recently, Ms Andrews served from May 2011 until May 2014 as General Counsel at Vertex Pharmaceuticals Incorporated, a biopharmaceutical company focussed on small molecule therapies for cystic fibrosis and other indications. From 2002 to May 2011, Ms Andrews served in various legal roles at Vertex, including as Deputy General Counsel and Chief Compliance Officer. Prior to joining Vertex, Ms Andrews was the Executive Director of Licensing for Massachusetts General Hospital and Brigham and Women’s Hospital from September 2001 to March 2002. From 1989 to 2001, Ms Andrews served as a corporate lawyer at Hill & Barlow PC, where she became a partner in 1997. In her professional roles, Ms Andrews has garnered expertise in areas including corporate strategy, strategic transactions, corporate governance, executive compensation, risk management, and compliance. Ms Andrews has served as a Non-Executive Director of Juniper Pharmaceuticals Inc, from 2005 until 2015. Ms Andrews received a BA in Chemistry and Psychology from Duke University and a JD from Boston College.


Mr Wurzer has served as a member of the Board of Directors since February 2015. Mr Wurzer is currently the Executive Vice President and Chief Investment Officer at Connecticut Innovations, a state-funded venture capital fund, where he previously served as Senior Managing Director and Managing Director. Prior to joining Connecticut Innovations in November 2009, Mr Wurzer served as Executive Vice President, Treasurer and Chief Financial Officer at CuraGen Corporation from 1997 to 2008. He also held numerous positions at Value Health Inc from 1991 to 1997, including Senior Vice President, Treasurer and Chief Financial Officer. Mr Wurzer is a Certified Public Accountant and began his career with Coopers & Lybrand, which is now part of PricewaterhouseCoopers. Mr Wurzer is a Non-Executive Director on the boards of Special Diversified Opportunities Inc, Thetis Pharmaceuticals LLC, My Gene Counsel LLC, Natural Polymer Devices and Axerion Therapeutics, Inc., and from 2010 to 2012 he was a Non-Executive Director on the board of DUSA Pharmaceuticals. He received a BBA from the University of Notre Dame.